drugset / Trial / NCT04927195
Study in Healthy Participants and Participants With Moderate Atopic Dermatitis & Optionally, Moderate Psoriasis, and/or Mild Asthma
RandomizedParallel-groupDouble-blindTreatment
Summary
This Phase 1 study will investigate the safety and tolerability of EDP1867 in healthy volunteers, participants with atopic dermatitis, and, optionally, in participants with psoriasis and/or asthma.
Timeline
- Start
- 2021-02-23
- Primary completion
- 2022-02-28
- Completion
- 2022-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EDP1867 | Other / unclassified | 7.5e+11 cells | Oral |
| Subject | EDP1867 | Other / unclassified | 1.5e+12 cells | Oral |